Products Categories
| CAS No.: | 728-88-1 |
|---|---|
| Name: | Tolperisone |
| Article Data: | 3 |
| Molecular Structure: | |
|
|
|
| Formula: | C16H23 N O |
| Molecular Weight: | 245.365 |
| Synonyms: | Propiophenone,2,4'-dimethyl-3-piperidino- (7CI,8CI); (?à)-Tolperisone; 2,4'-Dimethyl-3-piperidinopropiophenone;Mideton; Mydeton; Mydetone; NSC 107321; Tolperisone; dl-Tolperisone |
| EINECS: | 211-976-4 |
| Density: | 1.004g/cm3 |
| Melting Point: | 176.5°C |
| Boiling Point: | 373.9°C at 760 mmHg |
| Flash Point: | 134.4°C |
| Safety: | Poison by intravenous and intraperitoneal routes. Moderately toxic by ingestion and subcutaneous routes. When heated to decomposition it emits toxic fumes of NOx. |
| PSA: | 20.31000 |
| LogP: | 3.23760 |
- 81281-59-67-Benzylideneaminotheophylline
- 82993-81-5D-threo-Ritalinic acid hydrochloride
- 73441-42-6METHYL-5-CHLORO-2,2-DIMETHYLVALERATE
- 852475-26-4MC1568
- 958254-66-51H-Imidazo[4,5-b]pyridine-2-carboxaldehyde, 1-methyl-, hydrochloride
- 99170-93-1N-Methyl-2-oxazolamine
- 914458-26-7[5-(2-fluorophenyl)-1-pentyl-1H-pyrrol-3-yl]-1-naphthalenyl-Methanone
- 894852-01-87-BROMO-2,2-DIMETHYL-2H-PYRIDO[3,2-B][1,4]OXAZIN-3(4H)-ONE
- 90221-55-92-bromo-5-methylbenzaldehyde
- 885590-99-82,3-DIFLUORO-4-IODOBENZALDEHYDE
What can I do for you?
Get Best Price
Chemistry
IUPAC Name: 2-Methyl-1-(4-methylphenyl)-3-piperidin-1-ylpropan-1-one
The MF of Tolperisone (CAS NO.728-88-1) is C16H23NO.
The MW of Tolperisone (CAS NO.728-88-1) is 245.36.
Synonyms of Tolperisone (CAS NO.728-88-1): 1-Piperidino-2-methyl-3-(p-tolyl)-3-propanone ; 2,4'-Dimethyl-3-piperidino-propiophenon ; 2-Methyl-3-piperidino-1-p-tolylpropan-1-one ; 1-Propanone, 2-methyl-1-(4-methylphenyl)-3-(1-piperidinyl)-(9CI)
Index of Refraction: 1.526
EINECS: 211-976-4
Density: 1.004 g/ml
Flash Point: 134.4 °C
Boiling Point: 373.9 °C
Uses
Typically, Tolperisone (CAS NO.728-88-1) is indicated in the treatment of acute muscle spasms in back pain and spasticity in neurological diseases.
Toxicity Data With Reference
| 1. | orl-rat LD50:1450 mg/kg | OYYAA2 Oyo Yakuri. Pharmacometrics. 5 (1971),421. | ||
| 2. | ipr-rat LD50:170 mg/kg | OYYAA2 Oyo Yakuri. Pharmacometrics. 5 (1971),421. | ||
| 3. | scu-rat LD50:645 mg/kg | OYYAA2 Oyo Yakuri. Pharmacometrics. 5 (1971),421. | ||
| 4. | orl-mus LD50:1350 mg/kg | OYYAA2 Oyo Yakuri. Pharmacometrics. 5 (1971),421. | ||
| 5. | scu-mus LD50:620 mg/kg | ARZNAD Arzneimittel-Forschung. Drug Research. 11 (1961),257. | ||
| 6. | ivn-mus LD50:34 mg/kg | OYYAA2 Oyo Yakuri. Pharmacometrics. 5 (1971),421. |
Safety Profile
Poison by intravenous and intraperitoneal routes. Moderately toxic by ingestion and subcutaneous routes. When heated to decomposition it emits toxic fumes of NOx.
Specification
Tolperisone, a piperidine derivative, is a centrally acting muscle relaxant. Brand names include Mydocalm and Mydeton.
Tolperisone is currently marketed in Europe as a centrally-acting muscle relaxant which reportedly has special advantages over other drugs of its class in that it is reported not to cause drowsiness or lethargy according to some manufacturers.
Besides claiming that "Tolperisone has an excellent efficacy & safety profile" these manufacturers also state that Tolperisone has the unique property of mediating muscle relaxation without concomitant sedation nor does it cause impairment of coordination, weakness, mental confusion or withdrawal phenomena in contrast to other muscle relaxants.
Some people using Tolperisone have reported the following reactions:In hypersensitivity: muscle weakness, headache, arterial hypotension, nausea, vomiting, dyspepsia.Skin allergic reactions: skin rash, hives, Quincke's edema, anaphylactic shock.
The side effects and reactions listed above may not include all effects reported by the drug's manufacturer.
It is believed that Tolperisone has few interactions with other medicines. However, this doesn't rule out any interactions that may or may not have been reported to care-givers thus far.Some manufacturers have stated that Tolperisone may enhance the effects of other neuromuscular blocking agents.